Michael A. Kelly
Founder and President, Sentry Hill Partners, LLC
Michael is a former senior executive of Amgen, Inc. and is currently acting as Founder & President of Sentry Hill Partners, LLC, a global life sciences transformation and management consulting business founded by him in 2018. Mr. Kelly has more than two decades of executive experience as a senior leader in the life sciences industry serving in various strategic finance and operations positions at Amgen Inc., most recently as Senior Vice President, Global Business Services and Vice President & CFO, International Commercial Operations. He has also held positions at Biogen, Tanox, and Monsanto Life Sciences. Mr. Kelly is an independent member of the Board of Directors for publicly traded Amicus Therapeutics, DMC Global, Inc., NeoGenomics, Inc., and Prime Medicine, Inc. Previously, he served on the boards of Hookipa Pharma, Inc and Aprea Therapeutics, Inc. He also serves on the Council of Advisors and was the former audit committee chairman for Direct Relief, a humanitarian aid organization focused on health outcomes and disaster relief. Mr. Kelly holds a BSc in business administration from Florida A&M University, concentrating in Finance and Industrial Relations.